tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Cipla Ltd Confirms Regulatory Compliance with SEBI Regulations

Story Highlights
  • Cipla Ltd is a major pharmaceutical company in India, producing medicines for chronic diseases.
  • Cipla has confirmed compliance with SEBI regulations for dematerialization requests in Q3 2025.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Cipla Ltd Confirms Regulatory Compliance with SEBI Regulations

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An update from Cipla Ltd ( (IN:CIPLA) ) is now available.

Cipla Ltd has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming the processing of dematerialization requests for the quarter ending September 30, 2025. This announcement underscores Cipla’s compliance with regulatory requirements, ensuring that its securities are properly managed and listed on the relevant stock exchanges, thereby maintaining transparency and trust with its stakeholders.

More about Cipla Ltd

Cipla Ltd is a leading pharmaceutical company based in India, known for its extensive range of pharmaceutical products and services. The company focuses on the development and manufacturing of medicines to treat respiratory, cardiovascular, and other chronic diseases, making significant contributions to the healthcare industry.

Average Trading Volume: 51,685

Technical Sentiment Signal: Strong Buy

Current Market Cap: 1274.5B INR

For an in-depth examination of CIPLA stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1